The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
beta Blockade after myocardial infarction: systematic review and meta regression analysis
Open accessAbstract
OBJECTIVES: To assess the effectiveness of beta blockers in short term treatment for acute myocardial infarction and in longer term secondary prevention; to examine predictive factors that may influence outcome and therefore choice of drug; and to examine the clinical importance of the results in the light of current treatment. DESIGN: Systematic review of randomised controlled trials. SETTING: Randomised controlled trials. SUBJECTS: Patients with acute or past myocardial infarction. INTERVENTION: beta Blockers compared with control. MAIN OUTCOME MEASURES: All cause mortality and non-fatal reinfarction. RESULTS: Overall, 5477 of 54 234 patients (10.1%) randomised to beta blockers or control died. We identified a 23% reduction in the odds of death in long term trials (95% confidence interval 15% to 31%), but only a 4% reduction in the odds of death in short term trials (-8% to 15%). Meta regression in long term trials did not identify a significant reduction in effectiveness in drugs with cardioselectivity but did identify a near significant trend towards decreased benefit in drugs with intrinsic sympathomimetic activity. Most evidence is available for propranolol, timolol, and metoprolol. In long term trials, the number needed to treat for 2 years to avoid a death is 42, which compares favourably with other treatments for patients with acute or past myocardial infarction. CONCLUSIONS: beta Blockers are effective in long term secondary prevention after myocardial infarction, but they are underused in such cases and lead to avoidable mortality and morbidity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In those post-myocardial infarction and in heart failure patients, use of beta-blockade in carefully titrated doses is associated with improved outcomes.62,63”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [62]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Sleight, R. B., Sleight, P., Parish, S., Appleby, P. N., Collins, R., & Baigent, C. (1988) · PubMed · Cited by 2,868
The TIMI Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198903093201002 · Cited by 1,024
Gottlieb, S. S., McCarter, R., & Vogel, R. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808203390801 · Cited by 966
The Effect of Diltiazem on Mortality and Reinfarction after Myocardial Infarction
The Multicenter Diltiazem Postinfarction Trial Research Group (1988) · New England Journal of Medicine · doi:10.1056/nejm198808183190701 · Cited by 828
The Effect of Warfarin on Mortality and Reinfarction after Myocardial Infarction
Smith, P., Arnesen, H., & Holme, I. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007193230302 · Cited by 637
Research works printed but not linked: 3
- Viskin S, Barron HV. -Blockers prevent cardiac death following myocar- dial infarction: so why are so many infarct survivors discharge without -blockers? Am J Cardiol 1996;78:821-2.
- Spiegelhalter D, Thomas A, Best N, Gilks W. BUGS: Bayesian inference using Gibbs sampling, Version 0.50. Cambridge: Medical Research Council Biostatistics Unit, 1995.
- Feely J, de Vane PJ, Maclean D. -Blockers and sympathomimetics. BMJ 1983;286:1043-7.
Cited by
Sorted by citations
Items 401–500 of 1,000
Use of secondary preventive medications after the first attack of acute coronary syndrome
Salomaa, V. V., Pääkkönen, R., Hämäläinen, H., Niemi, M., & Klaukka, T. (2007) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000244573.10229.6e · Cited by 37
LaFleur, J., Nelson, R. E., Sauer, B. C., & Nebeker, J. R. (2011) · Heart · doi:10.1136/hrt.2011.223289 · Cited by 37
“The mean (SD) change from baseline for systolic BPs in each quarter following the index date ranged from 3.05 (25.2) mm Hg in the first quarter to 15.7 (30.0) mm Hg in the penultimate quarter for systolic BP and from 1.8 (14.8) mm Hg in the first quarter to 8.9 (16.0) mm Hg in the last quarter for diastolic BP.”
BackgroundInfluentialGaziano, T. A., Pandya, A., Sy, S., Jardim, T. V., Ogden, J. M., Rodgers, A., & Weinstein, M. C. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.04.020 · Cited by 35
FITCHETT, D. H., Théroux, P., Brophy, J. M., Cantor, W. J., Cox, J. L., Gupta, M., Kertland, H. R., Mehta, S. R., Welsh, R. C., & Goodman, S. G. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2011.08.110 · Cited by 37
The impact of specialists on prescribing by general practitioners
Robertson, J., Fryer, J., O’Connell, D. L., Sprogis, A., & Henry, D. A. (2001) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2001.tb143645.x · Cited by 36
Ezekowitz, J. A., Armstrong, P. W., Granger, C. B., Théroux, P., Stebbins, A. S., Kim, R. J., & Patel, M. R. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.05.035 · Cited by 34
Infarto agudo do miocárdio: síndrome coronariana aguda com supradesnível do segmento ST
Pesaro, A. E. P., Junior, C. V. S., & Nicolau, J. C. (2004) · Revista da Associação Médica Brasileira · doi:10.1590/s0104-42302004000200041 · Cited by 35
Hong, J. M., & Barry, A. R. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2110 · Cited by 35
Do Patients need Lifelong β-Blockers after an Uncomplicated Myocardial Infarction?
Zeitouni, M., Kernéis, M., Lattuca, B., Guedeney, P., Cayla, G., Collet, J., Montalescot, G., & Silvain, J. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00338-4 · Cited by 35
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
(2020) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2020.05.011 · Cited by 36
Schneeweiß, S., Patrick, A. R., Maclure, M., Dormuth, C. R., & Glynn, R. J. (2007) · PubMed · Cited by 35
Changes in baroreceptor sensitivity after eversion carotid endarterectomy
Demirel, S., Attigah, N., Bruijnen, H., Macek, L., Hakimi, M., Able, T., & Böckler, D. (2012) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2011.11.134 · Cited by 35
Austin, P. C., Tu, J. V., Ko, D. T., & Alter, D. A. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.071481 · Cited by 35
Explaining the increase in coronary heart disease mortality in Syria between 1996 and 2006
Rastam, S., Ali, R. A., Maziak, W., Mzayek, F., Fouad, F. M., O’Flaherty, M., & Capewell, S. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-754 · Cited by 35
Number Needed to Treat in Cardiac Rehabilitation
Oldridge, N., Perkins, A. J., Marchionni, N., Fumagalli, S., Fattirolli, F., & Guyatt, G. H. (2002) · Journal of Cardiopulmonary Rehabilitation · doi:10.1097/00008483-200201000-00003 · Cited by 35
Heller, D. A., Ahern, F. M., & Kozak, M. (2000) · American Heart Journal · doi:10.1067/mhj.2000.109650 · Cited by 35
Pathophysiology and prevention of sudden cardiac death
Goyal, V., Jassal, D. S., & Dhalla, N. S. (2015) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2015-0366 · Cited by 36
Bao, B., Ozasa, N., Morimoto, T., Furukawa, Y., Nakagawa, Y., Kadota, K., Iwabuchi, M., Shizuta, S., Shiomi, H., Tada, T., et al. (2012) · Cardiovascular Intervention and Therapeutics · doi:10.1007/s12928-012-0137-9 · Cited by 34
Guías de práctica clínica sobre prevención de la enfermedad cardiovascular: Versión resumida
Graham, I. D., Atar, D., Borch‐Johnsen, K., Boysen, G., Burell, G. K., Cífková, R., Dallongeville, J., Backer, G. D., Ebrahim, S. B. J., Gjelsvik, B., et al. (2008) · Revista Española de Cardiología · Cited by 33
Heart Rate: A Risk Factor for Cardiac Diseases and Outcomes?
Lanza, G. A., Fox, K. M., & Crea, F. (2006) · KARGER eBooks · doi:10.1159/000095401 · Cited by 34
Ohlsson, M. A., Kennedy, L. M. A., Juhlin, T., & Melander, O. (2014) · Resuscitation · doi:10.1016/j.resuscitation.2014.07.009 · Cited by 33
Delaney, J. A., Daskalopoulou, S. S., & Suissa, S. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1676 · Cited by 34
Sandhoff, B. G., Kuca, S., Rasmussen, J. R., & Merenich, J. A. (2008) · The Permanente Journal · doi:10.7812/tpp/08-007 · Cited by 34
Khànal, S., & Vadivelu, R. (2014) · Indian Heart Journal · doi:10.1016/j.ihj.2013.12.044 · Cited by 34
“increased bleeding risks in elderly, especially intracranial bleeding, as compared to primary PCI, but major trials testing this hypothesis had failed to prove it.(1,2) In fact, registry data show that less than 50% of the elderly patients receive any form of revascularization therapy despite suggested mortality benef…”
BackgroundResultTsujimoto, T., & Kajio, H. (2018) · Scientific Reports · doi:10.1038/s41598-018-27799-y · Cited by 32
Beta-blockers in patients without heart failure after myocardial infarction
Safi, S., Sethi, N. J., Korang, S. K., Nielsen, E. E., Feinberg, J. B., Gluud, C. N., & Jakobsen, J. C. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012565.pub2 · Cited by 36
Kunz, R., Burnand, B., & Schünemann, H. J. (2008) · Der Internist · doi:10.1007/s00108-008-2141-9 · Cited by 33
Sudden Cardiac Death and the Role of Medical Therapy
Arshad, A., Mandava, A., Kamath, G. S., & Musat, D. L. (2008) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2007.12.003 · Cited by 32
Tendera, M., Fox, K. M., Ferrari, R., Ford, I., Greenlaw, N., Abergel, H., Macarie, C., Tardif, J., Vardas, P. E., Zamorano, J., et al. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.06.052 · Cited by 33
“Since the time of the landmark beta-blocker trials in heart failure and post-MI [15–17,27], these agents have been used to prevent MI or death, and their cardioprotective effects have been broadly extrapolated to all patients with stable CAD, including those without MI.”
BackgroundKok, W., Björck, L., Nielsen, S., Novak, M., Sandström, T. Z., Jern, C., Torén, K., & Rosengren, A. (2013) · Stroke · doi:10.1161/strokeaha.113.002936 · Cited by 30
Fifth report on the provision of services for patients with heart disease
Hall, R. J., More, R. A. L., Camm, A. J., Swanton, H., Gray, H., Flint, J. L. M., Monro, J., Keogh, B. F., Dunn, F., Lewin, O., et al. (2002) · Heart · doi:10.1136/heart.88.suppl_3.iii1 · Cited by 33
Management of the patient with diabetes mellitus and myocardial infarction: clinical trials update
Klein, L., & Gheorghiade, M. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.10.020 · Cited by 33
Lobos, J. M., Royo‐Bordonada, M. Á., Brotons, C., Álvarez-Sala, L., Armario, P., Maiques, A., Mauricio, D., Sans, S., Villar, F., Lizcano‐Álvarez, A., et al. (2009) · PubMed · Cited by 32
Going Beyond the Grand Mean: Subgroup Analysis in Meta‐Analysis of Randomised Trials
Smith, G. D., & Egger, M. (2001) · Wiley eBooks · doi:10.1002/9780470693926.ch8 · Cited by 33
Pathak, A., & Mrabeti, S. (2021) · Vascular Health and Risk Management · doi:10.2147/vhrm.s285907 · Cited by 32
Lethal myocardial reperfusion injury: a necessary evil?
Ibáñez, B., Fuster, V., Jiménez-Borreguero, J., & Badimón, J. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.10.056 · Cited by 37
Hammal, F., Ezekowitz, J. A., Norris, C. M., Wild, T. C., Finegan, B. A., & Approach Investigators (2014) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-14-133 · Cited by 32
AlHabeeb, W., Mrabeti, S., & Abdelsalam, A. A. I. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07205-y · Cited by 32
Svensson, M. H. S., Schmidt, E. B., Jørgensen, K. A., & Christensen, J. H. (2007) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2007.02.004 · Cited by 32
Rezek, I., Mousan, G., Wang, Z., Murad, M. H., & Kallmes, D. F. (2013) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3598 · Cited by 32
The mechanism of action of omega-3 fatty acids in secondary prevention post-myocardial infarction
Harrison, N., & Abhyankar, B. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x17956 · Cited by 32
Chalmers, J. P., & Chapman, N. (2001) · Blood Pressure · doi:10.1080/080370501753400647 · Cited by 32
Risk of All-Cause Mortality in Diabetic Patients Taking β-Blockers
Tsujimoto, T., Kajio, H., Shapiro, M. F., & Sugiyama, T. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.11.019 · Cited by 30
Shavadia, J., Holmes, D. N., Thomas, L. E., Peterson, E. D., Granger, C. B., Roe, M. T., & Wang, T. Y. (2019) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.005103 · Cited by 31
“One-year β-blocker discontinuation rates of between 10% and 30% have previously been ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; KM, Kaplan-Meier; NSTEMI, non–ST-segment–elevation MI; and STEMI, STsegment–elevation MI. Circ Cardiovasc Qual Outcomes.”
BackgroundInfluentialСтароверов, И. И., Shakhnovich, R. M., Gilyarov, M. Y., Komarov, A. L., Константинова, Е. В., Панченко, Е. П., & Yavelov, I. S. (2020) · Eurasian heart journal · doi:10.38109/2225-1685-2020-1-4-77 · Cited by 33
Samidurai, M., Tarale, P., Janarthanam, C., Gomez-Estrada, C., Gordon, R., Zenitsky, G. D., Jin, H., Anantharam, V., Kanthasamy, A. G., & Kanthasamy, A. (2020) · Cells · doi:10.3390/cells9081831 · Cited by 31
Bongard, V., Cambou, J.-P., Leizorovicz, A., Ferrières, J., Vahanian, A. S., Jullien, G., Coppé, G., Guérillot, M., Herrmann, M. A., & Mas, J. (2004) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/00149831-200410000-00006 · Cited by 31
Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial
Rosselló, X., Domínguez‐Rodríguez, A., Latini, R., Sanchez, P. L., Raposeiras‐Roubín, S., Anguita, M. P., Barrabés, J. A., Grigis, G., Owen, R., Pocock, S., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf673 · Cited by 30
Gnjidic, D., Bennett, A., Couteur, D. G. L., Blyth, F., Cumming, R. G., Waite, L. M., Handelsman, D. J., Naganathan, V., Matthews, S. T., & Hilmer, S. N. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.045 · Cited by 30
Raposeiras‐Roubín, S., Abu‐Assi, E., Diéguez, A. R., González-Ferreiro, R., López-López, A., Bouzas‐Cruz, N., Castiñeira-Busto, M., Gil, C. P., García‐Acuña, J. M., & González‐Juanatey, J. R. (2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2014.07.028 · Cited by 30
Dransfield, M. T., McAllister, D., Anderson, J. A., Brook, R. D., Calverley, P. M. A., Celli, B. R., Crim, C. C., Gallot, N., Martínez, F. J., Scanlon, P. D., et al. (2018) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201708-626oc · Cited by 30
Does atenolol differ from other β-adrenergic blockers?
Aursnes, I., Osnes, J., Tvete, I. F., Gåsemyr, J., & Natvig, B. (2007) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-7-4 · Cited by 30
“Post myocardial infarction Unlike the other β-blockers, atenolol has not been shown to improve the long-term prognosis after myocardial infarction [5], nor has it been tested and shown to be an effective treatment for heart failure.”
Bauters, C., Lamblin, N., Ennezat, P. V., Mycinski, C., Tricot, O., Nugue, O., Segrestin, B., Hannebicque, G., Agraou, B., Polge, A. S., et al. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.01.009 · Cited by 30
Axtell, S. S., Ludwig, E. A., & Lopez‐Candales, A. (2001) · Clinical Cardiology · doi:10.1002/clc.4960240204 · Cited by 30
Sorensen, S. D., Macek, T. A., Cai, Z., Saugstad, J. A., & Conn, P. J. (2002) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12089-5 · Cited by 30
(ESC), G. D. T. S. D. Y. E. C. D. L. S. E. D. C., & (EASD), D. L. S. E. P. E. E. D. L. D. (2007) · Revista Española de Cardiología · doi:10.1016/s0300-8932(07)75070-4 · Cited by 28
Papel de los bloqueadores beta en la enfermedad cardiovascular en 2019
Martínez‐Milla, J., Raposeiras‐Roubín, S., Pascual-Figal, D. A., & Ibáñez, B. (2019) · Revista Española de Cardiología · doi:10.1016/j.recesp.2019.02.024 · Cited by 29
Systematic Reviews in Health Research
Egger, M., Higgins, J. P. T., & Smith, G. D. (2022) · Wiley eBooks · doi:10.1002/9781119099369.ch1 · Cited by 30
Godoy, L. C., Farkouh, M. E., Austin, P. C., Shah, B. R., Qiu, F., Jackevicius, C. A., Wijeysundera, H. C., Krumholz, H. M., & Ko, D. T. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.021 · Cited by 31
Bunch, T. J., Muhlestein, J. B., Bair, T. L., Renlund, D. G., LAPPE, D. L., Jensen, K. R., Horne, B. D., Carter, M. A., & Anderson, J. L. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.12.008 · Cited by 29
Is beta-blocker (atenolol) a preferred antihypertensive in acute intracerebral hemorrhage?
Kalita, J., Misra, U. K., & Kumar, B. (2012) · Neurological Sciences · doi:10.1007/s10072-012-1210-y · Cited by 29
Gemmell, I., Heller, R. F., Payne, K., Edwards, R., Roland, M. O., & Durrington, P. N. (2006) · BMJ Quality & Safety · doi:10.1136/qshc.2005.017061 · Cited by 29
Initiation of β-blocker therapy and depression after acute myocardial infarction
Ranchord, A. M., Spertus, J. A., Buchanan, D. M., GOSCH, K. L., & Chan, P. S. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.11.018 · Cited by 29
Beta blockers in patients with end‐stage renal disease—Evidence‐based recommendations
Weir, M. A., & Herzog, C. A. (2018) · Seminars in Dialysis · doi:10.1111/sdi.12691 · Cited by 29
Petersen, C. L., Nielsen, J. R., Petersen, B. L., & Kjær, A. (2003) · Cardiology · doi:10.1159/000072388 · Cited by 29
Bongard, V., Grenier, O., Ferrières, J., Danchin, N., Cantet, C., Amelineau, E., & Cambou, J. (2003) · International Journal of Cardiology · doi:10.1016/j.ijcard.2003.04.003 · Cited by 29
“Introduction ers [3], angiotensin-converting enzyme (ACE) inhibitors”
Hepatotoxicity of Cardiovascular and Antidiabetic Drugs
Marzio, D. H., & Navarro, V. J. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-387817-5.00029-7 · Cited by 29
β-blocker dosage and outcomes after acute coronary syndrome
Allen, J. E., Knight, S., McCubrey, R. O., Bair, T. L., Muhlestein, J. B., Goldberger, J. J., & Anderson, J. L. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.10.012 · Cited by 28
Extrinsically Conductive Nanomaterials for Cardiac Tissue Engineering Applications
Haq, A. U., Carotenuto, F., Nardo, P. D., Francini, R., Prosposito, P., Pescosolido, F., & Matteis, F. D. (2021) · Micromachines · doi:10.3390/mi12080914 · Cited by 28
Processes of Care and Outcomes for Community-Acquired Pneumonia
Lee, J. S., Primack, B. A., Mor, M. K., Stone, R. A., Obrosky, D. S., Yealy, D. M., & Fine, M. J. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.05.029 · Cited by 28
Survival of patients discharged after acute myocardial infarction and evidence-based drug therapy
Gouya, G., Reichardt, B., Ohrenberger, G., & Wolzt, M. (2007) · European Journal of Epidemiology · doi:10.1007/s10654-006-9087-9 · Cited by 28
Zhou, S., Paz, O., Cao, J., Asotra, K., Chai, N., Wang, C., Chen, L. S., Fishbein, M. C., Sharifi, B. G., & Chen, P. (2005) · Heart Rhythm · doi:10.1016/j.hrthm.2005.08.027 · Cited by 28
Al-Reesi, A., Al-Zadjali, N., Perry, J. J., Fergusson, D. A., Al-Shamsi, M., Al-Thagafi, M., & Stiell, I. G. (2008) · Canadian Journal of Emergency Medicine · doi:10.1017/s1481803500010137 · Cited by 28
Bjorck, L. M. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.203 · Cited by 27
Blood Pressure Management in Hemodialysis Patients: What We Know And What Questions Remain
Miskulin, D. C., & Weiner, D. E. (2017) · Seminars in dialysis · doi:10.1111/sdi.12586 · Cited by 26
Agarwal, M. A., Agrawal, S., Garg, L., Mohananey, D., Garg, A., Bhatia, N., & Lavie, C. J. (2017) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2017.05.004 · Cited by 28
Mengesha, H. G., Tafesse, T. B., & Bule, M. H. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00874 · Cited by 27
Ashrafian, H., & Violaris, A. G. (2005) · Primary Care Respiratory Journal · doi:10.1016/j.pcrj.2005.06.005 · Cited by 28
ED triage of patients with acute myocardial infarction: predictors of low acuity triage
Atzema, C. L., Austin, P. C., Tu, J. V., & Schull, M. J. (2010) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2009.03.010 · Cited by 28
Part 10: Pediatric Advanced Life Support
(2000) · Resuscitation · doi:10.1016/s0300-9572(00)00296-3 · Cited by 28
Practical considerations of β-blockade in the management of the post–myocardial infarction patient
Fonarow, G. C. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.02.008 · Cited by 28
Principles for national and regional guidelines on cardiovascular disease prevention
Smith, S. C., Voûte, J., & Fuster, V. (2006) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0655 · Cited by 28
Medical management of stable coronary artery disease.
Pflieger, M., Winslow, B. T., Mills, K., & Dauber, I. M. (2011) · PubMed · Cited by 27
Prognostic impact of ß-blocker use in patients with stable coronary artery disease
Bauters, C., Lemesle, G., Meurice, T., Tricot, O., de Groote, P., & Lamblin, N. (2014) · Heart · doi:10.1136/heartjnl-2014-305719 · Cited by 27
Effect of β‐Blockers Beyond 3 Years After Acute Myocardial Infarction
Park, J. J., Kim, S., Kang, S., Yoon, C., Cho, Y., Youn, T., Chae, I., & Choi, D. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007567 · Cited by 29
Ferreira, R. L. S., dos Anjos, M. A. S., Ledesma, E. F., Pereira, J. E. S., & Nóbrega, A. K. C. (2020) · Materiales de Construcción · doi:10.3989/mc.2020.02819 · Cited by 27
Gapp, O., Schweikert, B., Meisinger, C., & Holle, R. (2008) · Health Policy · doi:10.1016/j.healthpol.2008.03.009 · Cited by 27
Disparities in Cardiovascular Disease Risk and Treatment
Colleran, K., Richards, A. A., & Shafer, K. M. (2007) · Journal of Investigative Medicine · doi:10.2310/6650.2007.00028 · Cited by 27
Acute coronary syndromes in women: Is treatment different? should it be?
Bennett, S. K., & Redberg, R. F. (2004) · Current Cardiology Reports · doi:10.1007/s11886-004-0071-2 · Cited by 27
Delahaye, F., Bory, M., Cohen, A. A., Danchin, N., de Gévigney, G., Dellinger, A., Fraboulet, J.-Y., Gayet, J.-L., Guize, L., Iung, B., et al. (2001) · PubMed · Cited by 27
Beta-blocker Use in ST-segment Elevation Myocardial Infarction in the Reperfusion Era (GRACE)
Park, K. L., Goldberg, R. J., Anderson, F. A., López-Sendón, J. L., Montalescot, G., Brieger, D. B., Eagle, K. A., Wyman, A. S., & Gore, J. M. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.02.009 · Cited by 26
Anstensrud, A. K., Molden, E., Haug, H., Qazi, R., Muriq, H., Fosshaug, L. E., Spigset, O., & Øie, E. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02832-0 · Cited by 26
Chen, L., Huang, Z., Lü, J., Yang, Y., Pan, Y., Bao, K., Wang, J., Chen, W., Liu, J., Liu, Y., et al. (2021) · Clinical Interventions in Aging · doi:10.2147/cia.s308569 · Cited by 26
Acute myocardial infarction leads to acceleration of atherosclerosis
Wang, H., & Eitzman, D. T. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.04.004 · Cited by 26
Arrhythmic Complications of Acute Coronary Syndromes
Perron, A. D., & Sweeney, T. W. (2005) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2005.07.002 · Cited by 26
“In contradistinction, early use of beta-blockers in patients who experience AMI has been shown not only to reduce the incidence of VF but also mortality [6,73,74].”
BackgroundUpdate on the medical treatment of stable angina
Gayet, J.-L., Paganelli, F. F., & Solal, A. C. (2011) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2011.08.001 · Cited by 26
Myocardial infarction: management of the subacute period.
Mercado, M. G., Smith, D. K., & McConnon, M. L. (2013) · PubMed · Cited by 26
Challenges in Assessing the Process–Outcome Link in Practice
Parast, L. M., Doyle, B. J., Damberg, C. L., Shetty, K. D., Ganz, D. A., Wenger, N. S., & Shekelle, P. (2015) · Journal of General Internal Medicine · doi:10.1007/s11606-014-3150-0 · Cited by 26
Drug Therapy for Prevention of Recurrent Myocardial Infarction
van der Elst, M. E., Buurma, H., Bouvy, M. L., & de Boer, A. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c450 · Cited by 26
Acute myocardial infarction in Estonia: clinical characteristics, management and outcome
Ainla, T. (2005) · DSpace repository (University of Tartu) · Cited by 26
Metadata
- Authors
- Freemantle, N., Cleland, J., Young, P., Mason, J., & Harrison, J.
- Affiliations
- University of York (GB)
- University of Hull (GB)
- Corresponding author
- Freemantle, N.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 1999-06-26
- Volume
- 318
- Issue
- 7200
- Pages
- 1730-1737
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- PMC
- PMC31101
- OpenAlex
- W2070568974
- Cited by
- 1,509
- References
- 34
- Citations by year
- 2026: 27 · 2025: 43 · 2024: 38 · 2023: 30 · 2022: 42 · 2021: 36 · 2020: 49 · 2019: 47 · 2018: 53 · 2017: 57 · 2016: 58 · 2015: 48 · 2014: 67 · 2013: 74 · 2012: 83
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- BMJ (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Ischemia and Reperfusion
- Keywords
- beta-blockers, myocardial infarction, secondary prevention, all-cause mortality, reinfarction, cardioselectivity, intrinsic sympathomimetic activity, propranolol, timolol, metoprolol, number needed to treat, predictors of treatment response
- MeSH terms
- Adrenergic beta-Antagonists, Humans, Myocardial Infarction, Regression Analysis, Randomized Controlled Trials as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
